News from intarcia therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 13, 2014, 08:50 ET

Intarcia CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan

 Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P....

Dec 02, 2013, 14:37 ET

Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors

 Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career...

Sep 09, 2013, 09:36 ET

Intarcia Appoints Raymond Keane Vice President, General Counsel, And Chief Legal Officer

 Intarcia Therapeutics, Inc. today announced the appointment of Raymond T. Keane, Esq. to the position of Vice President, General Counsel and...

Jul 26, 2013, 08:35 ET

Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors

 Intarcia Therapeutics, Inc. today announced the appointment of Gino Santini to its Board of Directors. Mr. Santini is a former top executive...

Jul 17, 2013, 09:06 ET

Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs

 Intarcia Therapeutics, Inc. today announced the hiring of Dr. Eddie Li to the newly created position of Vice President and Global Head of...

Jun 13, 2013, 16:18 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies

Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more...

Mar 21, 2013, 09:12 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

Intarcia Therapeutics, Inc. announced today the enrollment of the first patients in FREEDOM-1, the first of four planned Phase 3 clinical trials...

Feb 05, 2013, 09:06 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development

 Intarcia Therapeutics, Inc. today announced the appointment of Owen Hughes, Jr., to the position of Chief Business Officer (CBO) and Head of...

Nov 15, 2012, 10:58 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes

 Intarcia Therapeutics, Inc. today announced the simultaneous completion of two financings with total proceeds of $210 million, the largest...

Oct 03, 2012, 08:45 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

Intarcia Therapeutics, Inc. announced the presentation of an analysis of phase 2 clinical study results for ITCA 650 (continuous subcutaneous...

Sep 28, 2012, 09:30 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

 Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous...

Apr 02, 2012, 09:05 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer

Intarcia Therapeutics, Inc. today announced that its Board of Directors has appointed Kurt Graves to the position of Chairman,...

Mar 27, 2012, 13:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer

 Intarcia Therapeutics, Inc. today announced the appointment of Michelle Baron, MD, FACE, to the position of Vice President...

Oct 21, 2011, 15:26 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the signing of a letter of intent with Quintiles, the world's leading biopharmaceutical services...

Sep 14, 2011, 12:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon

Intarcia Therapeutics, Inc. announced today the presentation of final 48-week results from a phase 2 clinical study of ITCA 650 (DUROS®...

Sep 12, 2011, 08:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes

Intarcia Therapeutics, Inc. announced today the presentation of three clinical abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery...

Jun 28, 2011, 12:45 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS®...

Jan 04, 2011, 15:07 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference

Intarcia Therapeutics, Inc. today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will present at the 29th Annual JP...

Nov 11, 2010, 16:15 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference

Intarcia Therapeutics. Inc today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will be presenting at the Lazard Capital...

Sep 22, 2010, 11:00 ET
Intarcia logo. (PRNewsFoto/Intarcia)

Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous...